1E Therapeutics

1E Therapeutics (1Etx) is a breakthrough, clinical stage drug development company creating first-in-class RNA-targeting therapeutics based on our proprietary drug design platform. 1E is the culmination of years of innovation, effort, and tens of millions of $US investment in research and development. 1E’s proprietary and groundbreaking rapid drug design process has proven uniquely able to develop innovative drugs that address chronic life threatening indications as well as emerging and evolving pathogens. 1E already has lead compounds that address a wide array of indications in oncology and age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders. 1E’s most advanced lead is already in a Phase 1/2 clinical trial, and the company is positioned to have multiple programs in the clinic within the next 2 years.
Active
February 2020
41
Software
B2B

people
Ido Bachelet
CTO
AI Expert Serial Entrepreneur

$120,000,000

Seed

December 8, 2021
Seed
$120,000,000

Date Announced

Round Stage

Round Size

Lead Investors

investor
Marius Nacht
Angel

Investor

Investor Type

Founded

Funds Raised

Artificial Intelligence

Register Pro to view more

Pro

$50 per month

Sign up to keep browsing

You reached your pageview limit

  • Save profiles to your list
  • Basic search functionality
  • Browse our leading AI database

Select a Table to Export